BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36902476)

  • 1. Gene Expression Analysis of Immune Regulatory Genes in Circulating Tumour Cells and Peripheral Blood Mononuclear Cells in Patients with Colorectal Carcinoma.
    Aktar S; Hamid FB; Gamage SMK; Cheng T; Parkneshan N; Lu CT; Islam F; Gopalan V; Lam AK
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between
    Aktar S; Islam F; Cheng T; Gamage SMK; Choudhury IN; Islam MS; Lu CT; Hamid FB; Ishida H; Abe I; Xie N; Gopalan V; Lam AK
    Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enumeration, characterisation and clinicopathological significance of circulating tumour cells in patients with colorectal carcinoma.
    Hamid FB; Lu CT; Matos M; Cheng T; Gopalan V; Lam AK
    Cancer Genet; 2021 Jun; 254-255():48-57. PubMed ID: 33610860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
    Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
    Hou J; Guo C; Lyu G
    Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
    Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M
    BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Heterogeneity of Single Circulating Tumour Cells in Colorectal Carcinoma.
    Hamid FB; Gopalan V; Matos M; Lu CT; Lam AK
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
    Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
    Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
    Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.
    Buim ME; Fanelli MF; Souza VS; Romero J; Abdallah EA; Mello CA; Alves V; Ocea LM; Mingues NB; Barbosa PN; Tyng CJ; Chojniak R; Chinen LT
    Cancer Biol Ther; 2015; 16(9):1289-95. PubMed ID: 26252055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
    Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH
    Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer.
    Cai J; Huang L; Huang J; Kang L; Lin H; Huang P; Zhu P; Wang J; Dong J; Wang L; Xian CJ
    J Cell Biochem; 2019 Apr; 120(4):4935-4941. PubMed ID: 30260024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
    Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.
    Ankeny JS; Court CM; Hou S; Li Q; Song M; Wu D; Chen JF; Lee T; Lin M; Sho S; Rochefort MM; Girgis MD; Yao J; Wainberg ZA; Muthusamy VR; Watson RR; Donahue TR; Hines OJ; Reber HA; Graeber TG; Tseng HR; Tomlinson JS
    Br J Cancer; 2016 Jun; 114(12):1367-75. PubMed ID: 27300108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.
    Catenacci DV; Chapman CG; Xu P; Koons A; Konda VJ; Siddiqui UD; Waxman I
    Gastroenterology; 2015 Dec; 149(7):1794-1803.e4. PubMed ID: 26341722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.